摘要
Abstract
Objectve:To explore the clinical effect of pegmolesatiole combined with roxadustat in the treatment of renal anemia.Method:A total of 92 patients with renal anemia admitted to Taizhou People's Hospital Affiliated to Nanjing Medical University from April 2023 to November 2024 were selected for a group study.The patients were divided into the observation group and the control group by drawing lots,with 46 cases in each group.Both groups of patients were treated with roxadustat.On this basis,the observation group was treated with pegmolesatiole.The prognosis of the two groups was compared.Result:After treatment,the observation group demonstrated significantly higher levels of hemoglobin and hematocrit compared to the control group(P<0.05),The levels of urea nitrogen and serum creatinine in obseravtion group were significantly lower than those of the control group,.Furthermore,markers of inflammation including high-sensitivity C-reactive protein,tumor necrosis factor-α,and interleukin-6—were all significantly reduced in the observation group relative to the controls(P<0.05).Nutritional status also improved,as evidenced by higher albumin and prealbumin levels in the observation group(P<0.05).However,there were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:On the basis of roxadustat in the treatment of renal anemia,the addition of Pegmolesatide can further enhance the therapeutic effect and improve the nutritional status of patients.Meanwhile,the combined regimen has good safety.关键词
肾性贫血/罗沙司他/培膜沙肽/肾功能/营养状态Key words
Renal anemia/Roxadustat/Pegmolesatide/Renal function/Nutritional status
